Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LSS | P48449 | 1/20 | 0.45 |
| ▸ | TOP2A | P11388 | 1/20 | 0.45 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23541336 | 0.93 | BRD4 (0.48) | CA2CA12CA3CA6CA9 | |
| SCHEMBL5664054 | 0.91 | LSS (0.55) | CA2CA12CA3CA6CA9 | |
| SCHEMBL2515185 | 0.89 | CA2 (0.43) | CA2CA12CA3CA6CA9 | |
| SCHEMBL21831305 | 0.89 | ALDH1A1 (0.67) | CA2CA12CA3CA6CA9 | |
| SCHEMBL1348988 | 0.89 | MAOA (0.53) | CA2CA12CA3CA6CA9 | |
| SCHEMBL23882679 | 0.89 | MAOB (0.53) | CA2CA12CA3CA6CA9 | |
| SCHEMBL1349663 | 0.89 | KDM4E (0.48) | CA2CA12CA3CA6CA9 | |
| SCHEMBL30251242 | 0.87 | CYP19A1 (0.53) | CA2CA12CA3CA6CA9 | |
| SCHEMBL17338939 | 0.87 | CYP19A1 (0.53) | CA2CA12CA3CA6CA9 | |
| SCHEMBL29044346 | 0.85 | MMP3 (0.50) | CA2CA12CA9CA14CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538230-B2 | Letrozole production process | CHEMAGIS LTD. (IL) | 2009-05-26 | — | — | US | claimed |
| US-20070112202-A1 | Letrozole production process | CHEMAGIS LTD. (IL) | 2007-05-17 | — | — | US | claimed |
| US-20070100149-A1 | PROCESS FOR PREPARING LETROZOLE | DR. REDDY'S LABORATORIES, INC. | 2007-05-03 | — | — | US | claimed |
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-08-05 | — | — | US | disclosed |
| US-20240294514-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2024-09-05 | — | — | US | disclosed |
| US-20230117674-A1 | MICROFLUIDIC REACTOR FOR CONTROLLING CHEMICAL REACTION AND CHEMICAL REACTION CONTROL METHOD USING THE SAME | POSTECH Research and Business Development Foundation (KR) | 2023-04-20 | — | — | US | disclosed |
| CN-115884613-A | Organic electroluminescent device | 固安翌光科技有限公司 | 2023-03-31 | — | — | CN | disclosed |
| EP-3154941-B1 | SMALL MOLECULE LFA-1 INHIBITORS | ALLOCYTE PHARMACEUTICALS AG (CH) | 2021-01-20 | — | — | EP | disclosed |
| CN-106470973-B | Small molecule L FA-1 inhibitor | 阿罗赛特制药公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20190040008-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ALLOCYTE PHARMACEUTICALS AG (CH) | 2019-02-07 | — | — | US | disclosed |
| US-10077238-B2 | Small molecule LFA-1 inhibitors | ALLOCYTE PHARMACEUTICALS AG (CH) | 2018-09-18 | — | — | US | disclosed |
| US-20070112203-A1 | The impurity isoletrozole is more rapidly oxidized to 4,4'-dicyanobenzophenone than Letrozole, which can be seperated by crystallization to yield highly purified letrozole | CHEMAGIS LTD. (IL) | 2007-05-17 | — | — | US | disclosed |
| US-20070112202-A1 | Letrozole production process | CHEMAGIS LTD. (IL) | 2007-05-17 | — | — | US | disclosed |
| US-20070100149-A1 | PROCESS FOR PREPARING LETROZOLE | DR. REDDY'S LABORATORIES, INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070100149-A1 | PROCESS FOR PREPARING LETROZOLE | DR. REDDY'S LABORATORIES, INC. | 2007-05-03 | — | — | US | disclosed |
| EP-1423381-B1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORP (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2004100978-A1 | A METHOD OF MODULATING CELLULAR TRANSMIGRATION AND AGENTS FOR USE THEREIN | MEDVET SCIENCE PTY. LTD. (AU) | 2004-11-25 | — | — | WO | disclosed |
| EP-0408509-B1 | Substituted benzonitriles | CIBA GEIGY AG (CH) | 1996-03-06 | — | — | EP | disclosed |
| US-5073574-A | TETRAZOLYL SUBSTITUTED BENZONITRILES AND ANTI-TUMOR USE THEREOF | CIBA-GEIGY CORPORATION (US) | 1991-12-17 | — | — | US | disclosed |
| EP-0408509-A2 | Substituted benzonitriles | CIBA-GEIGY AG (CH) | 1991-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100149-A1 | PROCESS FOR PREPARING LETROZOLE | CYP19A1, CYP2C19, CYP17A1 | CA2 4386/4885CA12 3483/4885CA3 3558/4885 |
| US-10077238-B2 | Small molecule LFA-1 inhibitors | ICAM1, VCAM1, ITGB1 | CA2 3924/4885CA12 3688/4885CA3 4417/4885 |
| US-20190040008-A1 | SMALL MOLECULE LFA-1 INHIBITORS | ICAM1, VCAM1, ITGB1 | CA2 3924/4885CA12 3688/4885CA3 4417/4885 |
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | MGLL, PNLIP, LPL | CA2 4149/4885CA12 4075/4885CA3 3327/4885 |
| US-20070112203-A1 | The impurity isoletrozole is more rapidly oxidized to 4,4'-dicyanobenzophenone than Letrozole, which can be seperated by crystallization to yield highly purified letrozole | CYP19A1, HSD17B11, SHBG | CA2 2649/4885CA12 3122/4885CA3 2039/4885 |
| US-20240294514-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | MGLL, PNLIP, LPL | CA2 4149/4885CA12 4075/4885CA3 3327/4885 |
| US-20070112202-A1 | Letrozole production process | CYP19A1, CDK14, CDK19 | CA2 2012/4885CA12 2467/4885CA3 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.